Showing results (2131-2140 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|September 29, 2012
Exploring QSARs of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitors by MLR, PLS and PC-ANNOmar Deeb, Sana Jawabreh, Mohammad GoodarziCurrent Pharmaceutical Design|September 29, 2012
Molecular modeling and virtual screening of DNA methyltransferase inhibitorsJosé L Medina-Franco, Jakyung YooCurrent Pharmaceutical Design|September 29, 2012
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesFederico Andreoli, Arménio Jorge Moura Barbosa, Marco Daniele Parenti, et al.Current Pharmaceutical Design|September 29, 2012
New insights into the treatment of multiple myeloma with histone deacetylase inhibitorsMichele Cea, Antonia Cagnetta, Marco Gobbi, et al.Current Pharmaceutical Design|September 29, 2012
ADP-ribosylated proteins as old and new drug targets for anticancer therapy: the example of ARF6Nadia Dani, Armenio Jorge Moura Barbosa, Alberto Del Rio, et al.Current Pharmaceutical Design|September 29, 2012
Wnt/beta-catenin signaling and small molecule inhibitorsAndrey Voronkov, Stefan KraussCurrent Pharmaceutical Design|September 15, 2012
Antimalarial drug resistance and early drug discoveryJose F Garcia-Bustos, Francisco-Javier GamoCurrent Pharmaceutical Design|September 15, 2012
The need for new antimalarial drugs less prone to resistanceHarald NoedlCurrent Pharmaceutical Design|September 15, 2012
Plasmodium drug targets outside the genetic control of the parasiteDavid J SullivanCurrent Pharmaceutical Design|September 15, 2012
Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathwayGiacomo Cossa, Laura Gatti, Giuliana Cassinelli, et al.Pageof 1,008